2019 logo_150x35_jpg.jpg
Novan Reports Full Year 2021 Financial Results and Provides Corporate Update
February 22, 2022 07:00 ET | Novan, Inc.
– First New Drug Application (NDA) submission targeted in Q4 2022 for lead program SB206 (berdazimer gel 10.3%) for molluscum contagiosum – – Ongoing advancement of priority development pipeline...
2019 logo_150x35_jpg.jpg
Novan to Report Full Year 2021 Financial Results on February 22, 2022
February 15, 2022 09:00 ET | Novan, Inc.
DURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February...
2019 logo_150x35_jpg.jpg
Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference
January 14, 2022 09:05 ET | Novan, Inc.
DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s completed Phase 2 and Phase 3 clinical studies of...
2019 logo_150x35_jpg.jpg
Novan to Participate in the Virtual Investor Roundtable Event
November 12, 2021 09:00 ET | Novan, Inc.
– Live moderated video webcast discussion among management and Pediatric Dermatology Thought Leader on Wednesday, November 17th at 1:00 PM ET – DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) --...
2019 logo_150x35_jpg.jpg
Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 10, 2021 05:55 ET | Novan, Inc.
– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum – –...
2019 logo_150x35_jpg.jpg
Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19
November 09, 2021 08:35 ET | Novan, Inc.
– Data indicate that intranasal administration of SB019 formulation containing berdazimer sodium is well-tolerated and safe under the conditions of preclinical study – – Company believes the...
2019 logo_150x35_jpg.jpg
Novan Announces Fireside Chat Hosted by Jonathan Aschoff, Ph.D. of ROTH Capital Partners
November 04, 2021 09:00 ET | Novan, Inc.
– Company highlights rationale of strategic pathway towards potential commercialization in collaboration with commercial solutions provider, Syneos Health – – Discusses recent progress and expected...
2019 logo_150x35_jpg.jpg
Novan to Report Third Quarter 2021 Financial Results on November 10, 2021
November 03, 2021 09:00 ET | Novan, Inc.
DURHAM, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2021 financial results on Wednesday,...
2019 logo_150x35_jpg.jpg
Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum
November 02, 2021 08:30 ET | Novan, Inc.
– Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care –– Company received...
2019 logo_150x35_jpg.jpg
Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206
September 23, 2021 08:00 ET | Novan, Inc.
– SB206 demonstrates continued favorable safety profile consistent with previous studies and meets Company’s expectations – – Pre-NDA meeting with the FDA, as well as conduct of customary stability...